Methods of Reducing Teratoma Formation During Allogeneic Stem Cell Therapy

Abstract

The present application relates to methods and compositions for treating diseased or damaged cardiac tissue comprising regenerative cells harvested from donor cardiac tissue. In one embodiment, regenerative cells are harvested from an allogeneic source and after administration result in increased viability and/or functional improvement of damaged or diseased cardiac tissue.

What is claimed is: 
     
         1 . A method for the reduction of teratoma formation following the delivery of nonself cells to a first subject, comprising:
 delivering to a first subject a population of regenerative cells,   wherein said regenerative cells are isolated from a tissue source harvested from a second subject,   wherein said regenerative cells express one or more factors that reduce teratoma formation,   wherein said at least a portion of said regenerative cells engraft into a target tissue of said first subject after delivery to said subject,   wherein said engraftment persists for a time period ranging from about 1 week to about 6 weeks,   wherein during said period of engraftment at least a portion of said regenerative cells are destroyed by the immune system of said first subject, and   wherein said engraftment of a portion of said regenerative cells, said period of engraftment, and said destruction of said regenerative cells reduces teratoma formation.